^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TC-A101

i
Other names: TC-A101, anti-ALPP CAR-T cells, retroviral vector-transduced autologous T cells to express anti-ALPP CARs, TCA101, TC A101
Company:
TCRCure, Xinqiao Hospital
Drug class:
ALPP-targeted CAR-T immunotherapy
Related drugs:
2ms
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
Enrollment open • CAR T-Cell Therapy • Metastases
|
MSLN (Mesothelin)
|
MSLN positive
|
cyclophosphamide • TC-A101
3ms
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=20, Suspended, Xinqiao Hospital of Chongqing | Recruiting --> Suspended
Trial suspension
|
MSLN (Mesothelin)
|
MSLN positive
|
cyclophosphamide • TC-A101
4ms
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
|
MSLN (Mesothelin)
|
cyclophosphamide • TC-A101